Optimizing the duration of anticoagulation therapy for venous thrombosis.
Year: 1999
Type: article
Abstract: Clinical research on venous thromboembolism hashelped to optimize the diagnosis and managementof deep vein thrombosis and pulmonary embolism. Clear concepts are emerging with respect to how best to provide initial therapy with unfractionated, or low-molecu-lar-weight, heparin. A number of studies have also at-tempted to establish the optimal duration of anticoagula-tion therapy in patients without concurrent malignant disease. In determining the length of treatment, the risk of thromboembolism recurring once the anticoagulant ther-apy is stopped must be weighed against the risk of bleeding if the therapy is continued. Although there are no definitive guidelines that apply to all patients, emerging evidence suggests that the risk of recurrent thromboembolism is suf-ficiently high in some patient groups to favour extended anticoagulation therapy. This high risk of recurrence is well known in patients with an underlying malignant dis-
Source: Europe PMC (PubMed Central)
Author: S Solymoss
Language: English
Subfield: Internal Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W137962260